Atossa Genetics
ATOSAtossa Genetics in brief
Atossa Genetics is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. Its market value was $26 M on 14 October 2026, which makes it the 23,585th largest listed company in the world and the 4,083rd largest in the USA on this site. Steven C. Quay is its chief executive. Its shares trade under the symbol ATOS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Atossa Genetics timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- 🔔· approximateInitial public offering on Nasdaq
- 2019
- ✎Renamed Atossa Therapeutics, Inc.Formerly Atossa Genetics Inc.
Events of Atossa Genetics from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,559 (Jan 2020) · #4,146 (Jan 2021) · #3,862 (Jan 2022) · #4,515 (Dec 2022) · #3,905 (Jul 2023) · #3,599 (Jan 2024) · #2,195 (Mar 2026) · #3,891 (Aug 2026) · #4,058 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -116.6%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -88.4%
- Liabilities / assets
- 17.3%
- Net debt
- $-8M
- Revenue growth
- +31.3%
- R&D / revenue
- 176.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-37M | $-35M | — |
| Dec 2024 | — | — | $-28M | $-26M | — |
| Dec 2023 | — | — | $-31M | $-30M | — |
| Dec 2022 | — | — | $-28M | $-27M | — |
| Dec 2021 | — | — | $-21M | $-21M | — |
| Dec 2020 | — | — | $-15M | $-18M | — |
| Dec 2019 | — | — | $-17M | $-17M | — |
| Dec 2018 | — | — | $-11M | $-11M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-30M | $0M | $-30M | $-4.04 | — |
| Dec 2024 | $-21M | $0M | $-21M | $-3.04 | — |
| Dec 2023 | $-21M | $0M | $-21M | $-0.24 | — |
| Dec 2022 | $-21M | $0M | $-21M | $-0.21 | — |
| Dec 2021 | $-16M | $0M | $-16M | $-0.18 | — |
| Dec 2020 | $-12M | $0M | $-12M | $-1.97 | — |
| Dec 2019 | $-9M | $0M | $-9M | $-2.03 | — |
| Dec 2018 | $-9M | $0M | $-9M | $-5.50 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Oct 9, 20268-KCurrent reportMaterial agreement · Other events
- Sep 29, 20268-KCurrent reportOther events
- Sep 18, 20268-KCurrent reportRegulation FD disclosure
- Aug 7, 20268-KCurrent reportResults of operations
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Jun 11, 20268-KCurrent reportMaterial agreement
- May 8, 20268-KCurrent report
- May 8, 202610-QQuarterly report · period to Mar 2026
- May 8, 20268-KCurrent reportShareholder vote
- Apr 16, 20268-KCurrent reportOther events
Official filings of Atossa Genetics with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-37 M
- Net income
- $-35 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $48 M
- Total liabilities
- $8 M
- Total equity
- $39 M
As of December-2025
Top 35 institutional investors in Atossa Genetics#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 361,747 | 0 (0.00%) | 3.63% | $1 M | Nov 13, 2026 |
| 2 | BlackRock, Inc. | 168,621 | +4,263 (+2.59%) | 1.69% | $0 M | Nov 13, 2026 |
| 3 | Renaissance Technologies LLC | 109,907 | -22,136 (-16.76%) | 1.10% | $0 M | Nov 12, 2026 |
| 4 | Geode Capital Management, LLC | 95,577 | +3,195 (+3.46%) | 0.96% | $0 M | Nov 6, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 52,583 | 0 (0.00%) | 0.53% | $0 M | Nov 13, 2026 |
| 6 | State Street Corp | 39,761 | 0 (0.00%) | 0.40% | $0 M | Nov 12, 2026 |
| 7 | UBS Group AG | 30,508 | -52,112 (-63.07%) | 0.31% | $0 M | Nov 10, 2026 |
| 8 | Ameriprise Financial Inc | 27,412 | -230,822 (-89.38%) | 0.27% | $0 M | Nov 16, 2026 |
| 9 | Susquehanna International Group, LLP | 21,513 | +5,939 (+38.13%) | 0.22% | $0 M | Nov 16, 2026 |
| 10 | Northern Trust Corp | 20,213 | -36 (-0.18%) | 0.20% | $0 M | Nov 16, 2026 |
| 11 | Millennium Management LLC | 14,867 | -31,641 (-68.03%) | 0.15% | $0 M | Nov 16, 2026 |
| 12 | Morgan Stanley | 12,345 | 0 (0.00%) | 0.12% | $0 M | Nov 13, 2026 |
| 13 | Royal Bank Of Canada | 4,885 | +2,891 (+144.98%) | 0.05% | $0 M | Nov 16, 2026 |
| 14 | Vanguard Global Advisers, LLC | 3,089 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 15 | Barclays PLC | 2,558 | New | 0.03% | $0 M | Nov 6, 2026 |
| 16 | Jones Financial Companies Lllp | 2,061 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 17 | NewEdge Advisors, LLC | 1,127 | New | 0.01% | $0 M | Nov 13, 2026 |
| 18 | Osaic Holdings, Inc. | 587 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 19 | Rockefeller Capital Management L.P. | 333 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Rydar Equities, Inc. | 333 | New | 0.00% | $0 M | Oct 13, 2026 |
| 21 | Harbour Investments, Inc. | 176 | +66 (+60.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 22 | SBI Securities Co., Ltd. | 148 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 23 | Wells Fargo & Company/mn | 145 | -83 (-36.40%) | 0.00% | $0 M | Nov 16, 2026 |
| 24 | BFC Planning, Inc. | 124 | New | 0.00% | $0 M | Nov 13, 2026 |
| 25 | TD Waterhouse Canada Inc. | 103 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
Show all 35: investors 26 to 35
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | BNP Paribas Financial Markets | 87 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 27 | NBH Bank | 69 | New | 0.00% | $0 M | Nov 5, 2026 |
| 28 | Allworth Financial LP | 66 | New | 0.00% | $0 M | Nov 17, 2026 |
| 29 | Bolton Securities Corporation | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 30 | FMR LLC | 35 | New | 0.00% | $0 M | Nov 10, 2026 |
| 31 | IFP Advisors, Inc | 29 | New | 0.00% | $0 M | Oct 16, 2026 |
| 32 | Caitong International Asset Management Co., Ltd | 8 | +2 (+33.33%) | 0.00% | $0 M | Oct 29, 2026 |
| 33 | Bogart Wealth, LLC | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 34 | Clearstead Advisors, LLC | 4 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 35 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Atossa Genetics#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 256,137 | $0 M | 2.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 201,434 | $0 M | 2.0% | 0.02% | +6.4% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 46,409 | $0 M | 0.47% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 99,071 | $0 M | 0.99% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 14,382 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 36,383 | $0 M | 0.36% | 0.02% | −4.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 12,643 | $0 M | 0.13% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 29,203 | $0 M | 0.29% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 4,211 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,539 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,986 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 952 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Atossa Genetics#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jonathan FinnDirector | Grant or award | +10,000 | — | — | 11,666 | Form 4 |
| filed | Shu-Chih ChenDirector | Grant or award | +10,000 | — | — | 10,000 | Form 4 |
| filed | H. Lawrence RemmelDirector | Grant or award | +10,000 | — | — | 10,683 | Form 4 |
| filed | Tessa CiglerDirector | Grant or award | +10,000 | — | — | 10,000 | Form 4 |
| filed | Stephen J. GalliDirector | Grant or award | +10,000 | — | — | 10,006 | Form 4 |
| filed | Richard I. SteinhartDirector | Grant or award | +10,000 | — | — | 10,000 | Form 4 |
| filed | Steven C. QuayPresident & CEO, Director | Grant or award | +65,000 | — | — | 88,038 | Form 4 |
| filed | Mark James DanielChief Financial Officer | Grant or award | +63,000 | — | — | 63,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Atossa Genetics#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-14.93 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0M |
| Q4 2022 | Q4 2023 | $0M |
Trading halts
- 2026-01-31 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 165 shares at $2.56
- : 31 shares at $2.39
- : 687 shares at $2.45
- : 1 shares at $2.34
- : 1,708 shares at $2.05
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Atossa Genetics scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 14, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-116.6%Free cash flow is -116.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.04 vs -3.04Diluted EPS -4.04 in fiscal 2025 against -3.04 the year before (report's currency).
- ✗Net income higher than five years earlier-$35 M-$35 M in fiscal 2025 against -$18 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-62.7%-62.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities5.5×Current ratio 5.52 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.6%Diluted shares up 2.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Atossa Genetics: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 21+50.1%— | 14−18.6%— | 17+14.9%— | 15+63.8%— | 9.2+39.4%— | 6.6r6.6−0.6%— | 6.6+57.8%— | 4.2+80.8%— | 2.3+202%— | 0.8—— | |
| General and administrative | 16+18.2%— | 14−3.8%— | 14+11.4%— | 13+11.5%— | 11+41.4%— | 8.0−24.7%— | 11+47.0%— | 7.2+48.7%— | 4.9−25.0%— | 6.5—— | |
| Operating expenses | 37+34.5%— | 28−12.0%— | 31+13.3%— | 28+34.9%— | 21+40.5%— | 15r15−15.4%— | 17+51.0%— | 11+49.5%— | 7.6−4.0%— | 8.0—— | |
| Operating income | −37—— | −28—— | −31—— | −28—— | −21—— | −15r−15—— | −17—— | −11—— | −7.6—— | −8.0—— | |
| Interest and finance income | 2.4−41.3%— | 4.1−6.7%— | 4.3+395%— | 0.9+14517%— | 0.0—— | — | — | — | — | — | |
| Other non-operating income (expense) | −0.0—— | −0.2—— | −0.1—— | −0.1—— | −0.1r−0.1−278%— | 0.1r0.1+98.8%— | 0.0−12.5%— | 0.0+18925%— | 0.0−100.0%— | 1.6—— | |
| Income before tax | −35—— | −26—— | −30—— | −27—— | −21—— | −18r−18—— | −17—— | −11—— | −8.1—— | −6.4—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | — | |
| Income from continuing operations | — | — | — | — | — | — | — | — | — | −6.4—— | |
| Net income attributable to shareholders | −35—— | −26—— | −30—— | −27—— | −21—— | −18r−18—— | −17—— | −11—— | −8.1—— | −6.4—— | |
| Earnings per share, basic | -4.04—— | -3.04r-0.20—— | -0.24—— | -0.21—— | -0.18—— | -1.97—— | -2.03—— | -5.50—— | -10.97r-0.91—— | -2.16r-2.80—— | |
| Earnings per share, diluted | -4.04—— | -3.04r-0.20—— | -0.24—— | -0.21—— | -0.18—— | -1.97—— | -2.03—— | -5.50—— | -10.97r-0.91—— | -2.16r-2.80—— | |
| Shares, weighted average (basic) | 8.6+2.6%— | 8.4r126−93.3%— | 126−0.4%— | 127r127+8.3%— | 117—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 8.6+2.6%— | 8.4r126−93.3%— | 126−0.4%— | 127+108172%— | 0.1+934%— | 0.0r11−99.9%— | 8.5+104%— | 4.2+327%— | 1.0r12−66.9%— | 2.9r2.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 41−41.9%86.7% | 71−19.6%93.0% | 88−20.2%91.9% | 111−18.7%89.8% | 136+245%96.5% | 40r40+214%92.3% | 13+21.2%86.8% | 10+43.8%88.6% | 7.2+138%88.4% | 3.0—73.1% | |
| Other current assets | 1.1−3.2%2.4% | 1.2−46.1%1.5% | 2.2−10.8%2.2% | 2.4+103%2.0% | 1.2+81.6%0.8% | 0.7r0.7+2414%1.5% | 0.0−15.6%0.2% | 0.0+89.3%0.3% | 0.0—0.2% | — | |
| Current assets | 46−38.7%95.8% | 74−19.3%97.4% | 92−22.0%95.8% | 118−16.3%95.7% | 141+230%100.0% | 43r43+199%99.8% | 14+24.0%98.8% | 12+46.2%98.5% | 7.9+143%96.7% | 3.3—78.5% | |
| Property, plant and equipment | — | — | — | — | 0.0−4.8%0.0% | 0.0r0.0−38.9%0.0% | 0.0−37.0%0.2% | 0.1+375%0.5% | 0.0−79.2%0.1% | 0.1—1.3% | |
| Right-of-use (leased) assets | — | — | — | 0—0.0% | 0−100%0.0% | 0.0r0.0−64.3%0.0% | 0.1—0.3% | — | — | — | |
| Other intangible assets | — | — | — | — | 0.1+31.7%0.0% | 0.0r0.1−76.4%0.1% | 0.2r0.2−9.6%1.2% | 0.2r0.2−17.9%1.6% | 0.2r0.1−63.5%2.9% | 0.6—15.5% | |
| Total assets | 48−37.7%100% | 76−20.6%100% | 96−22.1%100% | 124−12.6%100% | 141+230%100% | 43r43+196%100% | 14+23.6%100% | 12+43.6%100% | 8.2+97.0%100% | 4.1—100% | |
| Accounts payable | 4.3+532%9.0% | 0.7−15.8%0.9% | 0.8−72.8%0.8% | 3.0+72.7%2.4% | 1.7+8.1%1.2% | 1.6r1.6+442%3.7% | 0.3−17.0%2.0% | 0.4+5.5%3.0% | 0.3+31.7%4.1% | 0.3—6.1% | |
| Current liabilities | 8.3+66.2%17.3% | 5.0−5.1%6.5% | 5.2−6.0%5.4% | 5.6+78.1%4.5% | 3.1−80.1%2.2% | 16r16+1085%36.6% | 1.3−54.6%9.1% | 2.9+138%24.9% | 1.2+17.0%15.0% | 1.0—25.3% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | 0.0—0.1% | — | — | — | |
| Total liabilities | 8.3+66.2%17.3% | 5.0−5.1%6.5% | 5.2−6.0%5.4% | 5.6+78.1%4.5% | 3.1−80.1%2.2% | 16r16+1075%36.6% | 1.3−54.2%9.2% | 2.9—24.9% | — | 1.0—25.3% | |
| Retained earnings | −247—−518% | −212—−277% | −186—−194% | −156—−126% | −129—−91.5% | −112r−112—−261% | −94—−649% | −77—−656% | −65—−801% | −57—−1383% | |
| Shareholders' equity | 39−44.9%82.7% | 71−21.5%93.5% | 91−22.8%94.6% | 118−14.6%95.5% | 138+408%97.8% | 27r27+107%63.4% | 13r13+49.4%90.8% | 8.8+26.9%75.1% | 6.9+124%85.0% | 3.1—74.7% | |
| Total liabilities and equity | 48−37.7%100% | 76−20.6%100% | 96−22.1%100% | 124−12.6%100% | 141+230%100% | 43r43+196%100% | 14+23.6%100% | 12+43.6%100% | 8.2+97.0%100% | 4.1—100% | |
| Shares outstanding | 8.6+0.0%— | 8.6r129−93.1%— | 125−1.0%— | 127r127+0.0%— | 127+166%— | 48r48+421%— | 9.1+56.2%— | 5.8+120%— | 2.7r32−30.0%— | 3.8—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | 0.0−65.2%— | 0.0−51.1%— | 0.0r0.0−11.0%— | 0.1+19.4%— | 0.0−65.7%— | 0.1−57.5%— | 0.3—— | |
| Share-based compensation | 2.6+15.4%— | 2.3−50.4%— | 4.6−31.9%— | 6.8+28.9%— | 5.3+74.5%— | 3.0r3.0−57.5%— | 7.1r7.1+574%— | 1.1+33.9%— | 0.8−10.2%— | 0.9—— | |
| Cash from operating activities | −30—— | −21—— | −21—— | −21—— | −16—— | −12r−12—— | −9.1—— | −9.0—— | −6.6—— | −5.4—— | |
| Capital expenditure | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0r−0.0—— | −0.0—— | −0.1—— | — | — | |
| Cash from investing activities | −0.0—— | −0.0—— | −0.0—— | −4.7—— | −0.0—— | −0.0r−0.0—— | −0.0—— | −0.1—— | — | −0.0—— | |
| Shares issued | — | — | — | — | — | — | — | — | 6.2+31.2%— | 4.7—— | |
| Shares bought back | — | 0—— | −1.5—— | 0—— | — | — | — | — | — | — | |
| Cash from financing activities | 0−100%— | 3.7—— | −1.5—— | 0−100%— | 113+194%— | 39r39+240%— | 11−7.8%— | 12+14.0%— | 11+130%— | 4.7—— | |
| Change in cash | −30—— | −17—— | −22—— | −25−126%— | 97+259%— | 27r27+1126%— | 2.2−31.6%— | 3.2−23.2%— | 4.2—— | −0.7—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 19+4.2%— | 3.4−37.1%— | 4.9−11.0%— | 4.8+15.0%— | 6.2*+80.9%— | 5.4+57.4%— | 5.5+54.9%— | 4.2+10.9%— | 3.4*−39.8%— | 3.4—— | 3.6—— | 3.7—— | 5.7*—— | |
| General and administrative | 17+15.7%— | 2.5−35.0%— | 3.8+7.3%— | 5.1+56.3%— | 5.3*+40.9%— | 3.9+30.5%— | 3.5−0.4%— | 3.3+0.8%— | 3.7*+11.4%— | 3.0—— | 3.6—— | 3.2—— | 3.4*—— | |
| Operating expenses | 36+9.3%— | 5.9−36.2%— | 8.7−3.8%— | 9.9+33.1%— | 11*+59.9%— | 9.3+44.9%— | 9.0+27.2%— | 7.4+6.2%— | 7.2*−20.7%— | 6.4—— | 7.1—— | 7.0—— | 9.0*—— | |
| Operating income | −36—— | −5.9—— | −8.7—— | −9.9—— | −11*—— | −9.3—— | −9.0—— | −7.4—— | −7.2*—— | −6.4—— | −7.1—— | −7.0—— | −9.0*—— | |
| Interest and finance income | 1.2−57.2%— | 0.2−63.3%— | 0.2−64.8%— | 0.3−57.1%— | 0.4*−47.2%— | 0.6−43.1%— | 0.6−39.9%— | 0.7−36.7%— | 0.8*−32.3%— | 1.0—— | 1.1—— | 1.1—— | 1.2*—— | |
| Other non-operating income (expense) | 0.1—— | 0.1—— | −0.0—— | −0.0—— | 0.1*—— | −0.0—— | −0.0—— | −0.0—— | −0.0*−214%— | −0.1—— | −0.0—— | −0.0—— | 0.0*—— | |
| Income before tax | −35—— | −5.6—— | −8.5—— | −9.6—— | −11*—— | −8.7—— | −8.4—— | −6.7—— | −6.3*—— | −7.2—— | −6.0—— | −5.9—— | −7.8*—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | |
| Net income attributable to shareholders | −35—— | −5.6—— | −8.5—— | −9.6—— | −11*—— | −8.7—— | −8.4—— | −6.7—— | −6.3*—— | −7.2—— | −6.0—— | −5.9—— | −7.8*—— | |
| Earnings per share, basic | — | -0.56—— | -0.95—— | -1.11—— | — | -1.01r-0.07—— | -0.98r-0.07—— | -0.78r-0.05—— | — | -0.06—— | -0.05—— | -0.05—— | — | |
| Earnings per share, diluted | — | -0.56—— | -0.95—— | -1.11—— | — | -1.01r-0.07—— | -0.98r-0.07—— | -0.78r-0.05—— | — | -0.06—— | -0.05—— | -0.05—— | — | |
| Shares, weighted average (basic) | 10.0+15.9%— | 10.0+15.9%— | 8.9+3.3%— | 8.60.0%— | — | 8.6r129−93.1%— | 8.6r129−93.1%— | 8.6r129−93.1%— | — | 126—— | 126—— | 125—— | — | |
| Shares, weighted average (diluted) | 10.0+15.9%— | 10.0+15.9%— | 8.9+3.3%— | 8.60.0%— | — | 8.6r129−93.1%— | 8.6r129−93.1%— | 8.6r129−93.1%— | — | 126—— | 126—— | 125—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 21—77.8% | 21−60.3%77.8% | 26−54.9%80.8% | 32−51.3%83.6% | 41−41.9%86.7% | 52−30.7%89.4% | 58−27.2%89.7% | 65−22.4%92.0% | 71−19.6%93.0% | 75—94.1% | 80—92.6% | 84—92.2% | 88—91.9% | |
| Other current assets | 1.5—5.6% | 1.5+156%5.6% | 1.8+66.8%5.6% | 1.8+27.0%4.8% | 1.1−3.2%2.4% | 0.6−38.9%1.0% | 1.1+8.9%1.7% | 1.4−10.8%2.0% | 1.2−46.1%1.5% | 1.0—1.2% | 1.0—1.1% | 1.6—1.8% | 2.2—2.2% | |
| Current assets | 25—95.2% | 25−54.8%95.2% | 31−50.4%96.1% | 37−46.7%96.6% | 46−38.7%95.8% | 56−27.8%96.0% | 63−23.5%96.9% | 69−21.0%97.2% | 74−19.3%97.4% | 77—97.0% | 82—95.2% | 87—95.6% | 92—95.8% | |
| Total assets | 26—100% | 26−54.4%100% | 32−50.0%100% | 38−46.4%100% | 48−37.7%100% | 58−27.0%100% | 65−24.9%100% | 71−22.3%100% | 76−20.6%100% | 79—100% | 86—100% | 91—100% | 96—100% | |
| Accounts payable | 1.5—5.7% | 1.5−57.6%5.7% | 2.0−1.7%6.1% | 2.6+121%6.8% | 4.3+532%9.0% | 3.5+127%6.1% | 2.0+90.3%3.1% | 1.2−5.3%1.6% | 0.7−15.8%0.9% | 1.6—2.0% | 1.1—1.2% | 1.2—1.4% | 0.8—0.8% | |
| Current liabilities | 4.7—17.8% | 4.7−42.7%17.8% | 5.5−20.1%16.9% | 7.5+37.5%19.7% | 8.3+66.2%17.3% | 8.2+41.9%14.2% | 6.8+19.7%10.6% | 5.4+1.8%7.7% | 5.0−5.1%6.5% | 5.8—7.3% | 5.7—6.6% | 5.3—5.8% | 5.2—5.4% | |
| Total liabilities | 4.7—17.8% | 4.7−42.7%17.8% | 5.5−20.1%16.9% | 7.5+37.5%19.7% | 8.3+66.2%17.3% | 8.2+41.9%14.2% | 6.8+19.7%10.6% | 5.4+1.8%7.7% | 5.0−5.1%6.5% | 5.8—7.3% | 5.7—6.6% | 5.3—5.8% | 5.2—5.4% | |
| Retained earnings | −270—−1022% | −270—−1022% | −265—−820% | −256—−675% | −247—−518% | −236—−406% | −227—−352% | −219—−309% | −212—−277% | −205—−258% | −198—−231% | −192—−211% | −186—−194% | |
| Shareholders' equity | 22—82.2% | 22−56.3%82.2% | 27−53.5%83.1% | 30−53.3%80.3% | 39−44.9%82.7% | 50−32.4%85.8% | 58−28.0%89.4% | 65−23.8%92.3% | 71−21.5%93.5% | 74—92.7% | 80—93.4% | 86—94.2% | 91—94.6% | |
| Total liabilities and equity | 26—100% | 26−54.4%100% | 32−50.0%100% | 38−46.4%100% | 48−37.7%100% | 58−27.0%100% | 65−24.9%100% | 71−22.3%100% | 76−20.6%100% | 79—100% | 86—100% | 91—100% | 96—100% | |
| Shares outstanding | 10.0—— | 10.0−92.3%— | 10.0−92.3%— | 8.6−93.3%— | 8.6+0.0%— | 129+3.1%— | 129+3.1%— | 129+2.9%— | 8.6r129−93.1%— | 125—— | 125—— | 126—— | 125—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.6−11.3%— | 0.5−30.2%— | 0.8+2.4%— | 0.7+28.2%— | 0.5*−35.0%— | 0.8+4.7%— | 0.8+126%— | 0.6+35.0%— | 0.8*+49.1%— | 0.7—— | 0.4—— | 0.4—— | 0.5*—— | |
| Cash from operating activities | −35—— | −5.5*—— | −9.6*—— | −9.6—— | −11*—— | −6.0*—— | −7.3*—— | −6.0—— | −7.1*—— | −4.8*—— | −4.5*—— | −4.7—— | −5.6*—— | |
| Capital expenditure | −0.0—— | 0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | 0*—— | −0.0—— | 0*—— | −0.0*—— | −0.0*—— | −0.0—— | 0*—— | |
| Cash from investing activities | −0.0—— | 0*—— | 0*—— | 0—— | −0.0*—— | −0.0*—— | 0*—— | −0.0—— | 0*—— | −0.0*—— | −0.0*—— | −0.0—— | 0*—— | |
| Shares bought back | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from financing activities | 4.0+19.3%— | 0*—— | 4.0*—— | 0—— | 0*−100%— | 0*—— | 0*−100%— | 0−100%— | 3.4*—— | 0*—— | 0.1*—— | 0.2—— | 0*—— | |
| Change in cash | −31—— | −5.5*—— | −5.6*—— | −9.6—— | −11*—— | −6.0*—— | −7.3*—— | −6.0—— | −3.7*—— | −4.8*—— | −4.4*—— | −4.5—— | −5.6*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Atossa Genetics#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Quay | $2.5 M | $2.2 M | $759 K | — |
| 2024Dr. Quay | $2.8 M | $3.0 M | $1.1 M | $79 |
| 2023Dr. Quay | $2.4 M | $2.7 M | $1.4 M | — |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Atossa Genetics#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Directors and officers 1 · Material agreement 3 · Agreement ended 1 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Atossa Genetics#
$40 K spent on lobbying the US Congress and federal agencies in 2021, most often on medical/disease research/clinical labs.
- Medical/Disease Research/Clinical Labs1 report
Lobbying firms hired in 2021
Desimone Consulting, LLC $40 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2021 | $40 K | — | 1 |
| 2020 | $100 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Atossa Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Atossa Genetics compares in Biotechnology
- Market cap$26 M · higher than 20% of 726
- Revenue growth31.3% · higher than 67% of 438
- Price / book0.7× · lower than 87% of 534
- FCF yield-116.6% · higher than 9% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Atossa Genetics🇺🇸 | $26 M | — | — | +31.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 14, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Atossa Genetics? Verify and update this profile — free
Show Atossa Genetics's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.